Blog

CONFERENCE REFLECTIONS: TWO CROI “ROOKIES” DRAW INSPIRATION FROM CROI AT 30

CROI is a forum for scientists and clinical investigators to present, discuss, and critique their investigations into the epidemiology and biology of human retroviruses and associated diseases, including HIV and AIDS. It was the 30th year of the conference, but our first time attending. In this post, we reflect on what we learned and how we might apply key takeaways to our work on MOSAIC.

Continue Reading

Events

CHAMPIONING CHOICE IN A MULTI-PRODUCT HIV PREVENTION MARKET

New products, including the dapivirine vaginal ring and injectable cabotegravir, have been approved in several countries, and more biomedical prevention products are in development. As the catalog of HIV prevention products expands, so too does the conversation about the importance of upholding choice to optimize the benefits for potential PrEP users.

Continue Reading

Blog

LOCAL PARTNERSHIPS: PREPARING TO SUPPORT SUSTAINED ACCESS AND EFFECTIVE USE OF HIV PREVENTION PRODUCTS

The success of efforts to introduce new pre-exposure prophylaxis (PrEP) methods for HIV prevention, such as the PrEP ring and injectable CAB PrEP, will also rely on local partners. That’s why one of MOSAIC’s five strategic objectives is dedicated to strengthening local partner capacity to design and implement high-quality product introduction activities and research.

Continue Reading

Blog

A NEW OPTION TO TRANSFORM HIV PREVENTION

The future of HIV prevention is here. Injectable cabotegravir (CAB) is the most effective, longest-acting option for avoiding the virus. Until now, pre-exposure prophylaxis (or PrEP) medicine taken to prevent HIV has only been available as an oral pill that must be taken daily. CAB needs to be injected only once every two months.

Continue Reading